deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs
News Feb 09, 2009
deCODE chemistry & biostructures has announced the initiation of a collaboration with UCB. Under the terms of the deal, deCODE and UCB will collaborate on the structure-based discovery of small molecule modulators of undisclosed cytokine targets.
The program will focus on integrated structure-based drug design leveraging deCODE’s Fragments of Life™ technology for lead identification and optimization. As the program advances, it may also capitalize on deCODE's expertise in ADMET and PK/PD. The financial terms of the research fee, milestone and royalty-bearing relationship were not disclosed.